PET/MRI scanning in pre-surgical staging of high-risk prostate cancer patients

A small, Norwegian, Phase II clinical trial has explored the potential diagnostic value of [18F]fluciclovine PET/MRI scans of the pelvic lymph nodes in staging for patients with high-risk prostate cancer. … READ MORE …

Axumin PET/CT scans change treatment recommendations in recurrent prostate cancer

The value of many cancer-related tests is actually based on whether the results of the particular test change the way that  physicians plan to treat specific patients (hopefully for the better). … READ MORE …

Axumin-enhanced PET scans becoming more widely available

Because the new imaging agent known as [18F]fluciclovine (Axumin®) is the only such imaging agent approved for use in the US — other than the [11C]choline imaging agent (use of which is limited to the Mayo Clinic) — we have been monitoring access to this new agent with some interest. … READ MORE …

Increasing availability of the Axumin-enhanced PET scan

Back in May this year we reported that the US Food and Drug Administration had approved a new type of imaging agent known as [18F]fluciclovine (Axumin®) for use in association with PET scans in men with recurrent prostate cancer that might have spread to other parts of the body, but which was not evident on older forms of scan. … READ MORE …

New fluorine-18-based imaging agent approved in USA

Last Friday the US Food and Drug Administration (FDA) last Friday approved a new type of imaging agent for use in PET/CT scans for men with suspected prostate cancer recurrence after earlier treatment. … READ MORE …